

# Jenny Kw Lam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8615858/publications.pdf>

Version: 2024-02-01

67  
papers

3,219  
citations

159525

30  
h-index

155592

55  
g-index

69  
all docs

69  
docs citations

69  
times ranked

4894  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. <i>International Journal of Pharmaceutics</i> , 2022, 619, 121704.	2.6	6
2	Modification of KL4 Peptide Revealed the Importance of Alpha-Helical Structure for Efficient siRNA Delivery. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 220-228.	2.0	12
3	Comparative Effectiveness of Roflumilast and Azithromycin for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2021, 8, 450-463.	0.5	3
4	Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl- $\beta$ -Cyclodextrin as Excipient. <i>Pharmaceutics</i> , 2021, 13, 615.	2.0	11
5	Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance. <i>Molecular Pharmaceutics</i> , 2021, 18, 2218-2232.	2.3	12
6	Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses. <i>Current Pharmaceutical Design</i> , 2021, 27, 1453-1468.	0.9	9
7	Memory care approaches to better leverage capacity of dementia specialists: a narrative synthesis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 239-250.	1.2	3
8	Inhaled Dry Powder Formulation of Tamibarotene, a Broad-Spectrum Antiviral against Respiratory Viruses Including SARS-CoV-2 and Influenza Virus. <i>Advanced Therapeutics</i> , 2021, 4, 2100059.	1.6	12
9	Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy. <i>Pharmaceutics</i> , 2021, 13, 2044.	2.0	7
10	Inhaled RNA Therapy: From Promise to Reality. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 715-729.	4.0	58
11	A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. <i>Communications Biology</i> , 2020, 3, 697.	2.0	14
12	Pulmonary Delivery of Biological Drugs. <i>Pharmaceutics</i> , 2020, 12, 1025.	2.0	97
13	Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 234-243.	6.6	28
14	Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles. <i>International Journal of Pharmaceutics</i> , 2020, 584, 119444.	2.6	23
15	Intratracheal Administration of Dry Powder Formulation in Mice. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	10
16	A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. <i>Journal of Asthma</i> , 2019, 56, 872-881.	0.9	15
17	Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. <i>Journal of Controlled Release</i> , 2019, 314, 102-115.	4.8	117
18	High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118818.	2.6	16

#	ARTICLE	IF	CITATIONS
19	Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition. <i>International Journal of Pharmaceutics</i> , 2019, 560, 144-154.	2.6	42
20	Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. <i>International Journal of Cardiology</i> , 2019, 282, 53-58.	0.8	14
21	Research and Development of Proteins and Peptides with Therapeutic Potential from Yam Tubers. <i>Current Protein and Peptide Science</i> , 2019, 20, 277-284.	0.7	11
22	Chitosan-based nanosystems and their exploited antimicrobial activity. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 8-20.	1.9	196
23	Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery. <i>Asian Journal of Pharmaceutical Sciences</i> , 2018, 13, 163-172.	4.3	48
24	Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation. <i>International Journal of Pharmaceutics</i> , 2018, 552, 67-75.	2.6	38
25	Comparative Study of Diethylaminoethyl-Chitosan and Methylglycol-Chitosan as Potential Non-Viral Vectors for Gene Therapy. <i>Polymers</i> , 2018, 10, 442.	2.0	42
26	Synthesis, Structure-Activity Relationships and In Vitro Toxicity Profile of Lactose-Based Fatty Acid Monoesters as Possible Drug Permeability Enhancers. <i>Pharmaceutics</i> , 2018, 10, 81.	2.0	27
27	Rifampin- or Capreomycin-Induced Remodeling of the <i>Mycobacterium smegmatis</i> Mycolic Acid Layer Is Mitigated in Synergistic Combinations with Cationic Antimicrobial Peptides. <i>MSphere</i> , 2018, 3, .	1.3	11
28	Development of carrier-free, inhalable powder formulation of siRNA therapeutics for the treatment of respiratory diseases. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR20-5.	0.0	0
29	Steroidogenic effect of Erxian decoction for relieving menopause via the p-Akt/PKB pathway in vitro and in vivo. <i>Journal of Ethnopharmacology</i> , 2017, 195, 188-195.	2.0	24
30	TRIF-dependent Toll-like receptor signaling suppresses <i>Scd1</i> transcription in hepatocytes and prevents diet-induced hepatic steatosis. <i>Science Signaling</i> , 2017, 10, .	1.6	16
31	Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. <i>International Journal of Pharmaceutics</i> , 2017, 530, 40-52.	2.6	50
32	From Pulmonary Surfactant, Synthetic KL4 Peptide as Effective siRNA Delivery Vector for Pulmonary Delivery. <i>Molecular Pharmaceutics</i> , 2017, 14, 4606-4617.	2.3	33
33	Water-in-Oil Microemulsions for Protein Delivery: Loading Optimization and Stability. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 410-421.	0.9	5
34	Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside. <i>Molecules</i> , 2016, 21, 1249.	1.7	54
35	Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 21-32.	6.6	20
36	Incorporation of a Nuclear Localization Signal in pH Responsive LAH4-L1 Peptide Enhances Transfection and Nuclear Uptake of Plasmid DNA. <i>Molecular Pharmaceutics</i> , 2016, 13, 3141-3152.	2.3	46

#	ARTICLE	IF	CITATIONS
37	Chemicalâ€“physical properties and cytotoxicity of N -decanoyl amino acid-based surfactants: Effect of polar heads. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 2016, 492, 38-46.	2.3	33
38	Pulmonary delivery of rifampicin microspheres using lower generation polyamidoamine dendrimers as a carrier. <i>Powder Technology</i> , 2016, 291, 366-374.	2.1	35
39	PEGylated Biodegradable Polyesters for PGSS Microparticles Formulation: Processability, Physical and Release Properties. <i>Current Drug Delivery</i> , 2016, 13, 673-681.	0.8	7
40	A Novel, Stable, Estradiol-Stimulating, Osteogenic Yam Protein with Potential for the Treatment of Menopausal Syndrome. <i>Scientific Reports</i> , 2015, 5, 10179.	1.6	18
41	Inhalable Dry Powder Formulations of siRNA and pH-Responsive Peptides with Antiviral Activity Against H1N1 Influenza Virus. <i>Molecular Pharmaceutics</i> , 2015, 12, 910-921.	2.3	41
42	Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis. <i>International Journal of Pharmaceutics</i> , 2015, 491, 367-374.	2.6	37
43	Oleanolic Acid Loaded PEGylated PLA and PLGA Nanoparticles with Enhanced Cytotoxic Activity against Cancer Cells. <i>Molecular Pharmaceutics</i> , 2015, 12, 2112-2125.	2.3	38
44	siRNA Versus miRNA as Therapeutics for Gene Silencing. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e252.	2.3	730
45	Network pharmacological identification of active compounds and potential actions of Erxian decoction in alleviating menopause-related symptoms. <i>Chinese Medicine</i> , 2015, 10, 19.	1.6	65
46	Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation. <i>Current Pharmaceutical Design</i> , 2015, 21, 3854-3866.	0.9	30
47	Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. <i>Pharmaceutics</i> , 2014, 6, 378-415.	2.0	57
48	Oral transmucosal drug delivery for pediatric use. <i>Advanced Drug Delivery Reviews</i> , 2014, 73, 50-62.	6.6	105
49	Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 64-73.	2.0	49
50	Cationic amphipathic D-enantiomeric antimicrobial peptides with inÂvitro and exÂvivo activity against drug-resistant Mycobacterium tuberculosis. <i>Tuberculosis</i> , 2014, 94, 678-689.	0.8	42
51	Manipulating the pH response of 2,3-diaminopropionic acid rich peptides to mediate highly effective gene silencing with low-toxicity. <i>Journal of Controlled Release</i> , 2013, 172, 929-938.	4.8	9
52	Western Blot Evaluation of siRNA Delivery by pH-Responsive Peptides. <i>Methods in Molecular Biology</i> , 2013, 986, 73-87.	0.4	9
53	DNA-loaded chitosan oligosaccharide nanoparticles with enhanced permeability across Calu-3 cells. <i>Journal of Drug Targeting</i> , 2013, 21, 474-486.	2.1	18
54	Comprehensive Study on the Toxicology of Surface-Coated ZnO Nanoparticles in Human Alveolar Adenocarcinoma (A549) Cells. <i>Science of Advanced Materials</i> , 2013, 5, 421-429.	0.1	3

#	ARTICLE	IF	CITATIONS
55	Conformational Flexibility Determines Selectivity and Antibacterial, Antiplasmodial, and Anticancer Potency of Cationic $\alpha$ -Helical Peptides*. <i>Journal of Biological Chemistry</i> , 2012, 287, 34120-34133.	1.6	78
56	Biomedical applications of amino acid-modified chitosans: A review. <i>Biomaterials</i> , 2012, 33, 7565-7583.	5.7	123
57	Pulmonary delivery of therapeutic siRNA. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1-15.	6.6	177
58	Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways. <i>Journal of Controlled Release</i> , 2012, 158, 293-303.	4.8	41
59	The involvement of microtubules and actin filaments in the intracellular transport of non-viral gene delivery system. <i>Journal of Drug Targeting</i> , 2011, 19, 56-66.	2.1	9
60	Biomechanical Characterization of a Micro/Macroporous Polycaprolactone Tissue Integrating Vascular Graft. <i>Cardiovascular Engineering and Technology</i> , 2010, 1, 202-215.	0.7	3
61	Structural contributions to the intracellular targeting strategies of antimicrobial peptides. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 1934-1943.	1.4	63
62	An <i>in vitro</i> multi-parametric approach to measuring the effect of implant surface characteristics on cell behaviour. <i>Biomedical Materials (Bristol)</i> , 2010, 5, 015002.	1.7	10
63	Capturing local and anisotropic behaviour in surface topography. <i>Wear</i> , 2009, 266, 527-529.	1.5	3
64	Folate conjugated phosphorylcholine-based polycations for specific targeting in nucleic acids delivery. <i>Journal of Drug Targeting</i> , 2009, 17, 512-523.	2.1	19
65	Structural Study of DNA Condensation Induced by Novel Phosphorylcholine-Based Copolymers for Gene Delivery and Relevance to DNA Protection. <i>Langmuir</i> , 2005, 21, 3591-3598.	1.6	86
66	Phosphorylcholine- $\alpha$ -polycation diblock copolymers as synthetic vectors for gene delivery. <i>Journal of Controlled Release</i> , 2004, 100, 293-312.	4.8	103
67	Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems. , 0, , .		46